Cerus Co. (CERS) Director Gail Schulze Sells 52,500 Shares

Cerus Co. (NASDAQ:CERS) Director Gail Schulze sold 52,500 shares of Cerus stock in a transaction on Friday, June 8th. The shares were sold at an average price of $6.65, for a total transaction of $349,125.00. Following the completion of the sale, the director now owns 40,986 shares in the company, valued at $272,556.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Cerus opened at $6.65 on Wednesday, Marketbeat.com reports. Cerus Co. has a twelve month low of $2.10 and a twelve month high of $6.99. The company has a debt-to-equity ratio of 0.33, a quick ratio of 5.10 and a current ratio of 5.66. The stock has a market capitalization of $860.29 million, a PE ratio of -11.88 and a beta of 1.81.

Cerus (NASDAQ:CERS) last posted its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01. Cerus had a negative net margin of 111.46% and a negative return on equity of 111.19%. The firm had revenue of $13.56 million for the quarter, compared to the consensus estimate of $12.22 million. During the same period in the previous year, the firm posted ($0.18) EPS. The business’s quarterly revenue was up 93.4% on a year-over-year basis. equities analysts forecast that Cerus Co. will post -0.45 earnings per share for the current fiscal year.

A number of brokerages have issued reports on CERS. ValuEngine upgraded shares of Cerus from a “buy” rating to a “strong-buy” rating in a report on Friday, June 1st. BidaskClub downgraded shares of Cerus from a “strong-buy” rating to a “buy” rating in a report on Friday, June 8th. Zacks Investment Research upgraded shares of Cerus from a “sell” rating to a “hold” rating in a report on Thursday, May 24th. Finally, BTIG Research restated a “hold” rating on shares of Cerus in a report on Wednesday, May 9th. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $5.44.

Several institutional investors have recently bought and sold shares of the company. Millennium Management LLC increased its holdings in shares of Cerus by 103.7% in the 1st quarter. Millennium Management LLC now owns 1,740,398 shares of the biotechnology company’s stock worth $9,537,000 after buying an additional 886,056 shares during the last quarter. California State Teachers Retirement System increased its holdings in shares of Cerus by 8.5% in the 1st quarter. California State Teachers Retirement System now owns 193,666 shares of the biotechnology company’s stock worth $1,061,000 after buying an additional 15,163 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Cerus in the 1st quarter worth about $107,000. Element Capital Management LLC bought a new stake in shares of Cerus in the 1st quarter worth about $103,000. Finally, Barclays PLC grew its holdings in Cerus by 4.8% during the 1st quarter. Barclays PLC now owns 288,783 shares of the biotechnology company’s stock valued at $1,582,000 after purchasing an additional 13,122 shares during the last quarter. Hedge funds and other institutional investors own 60.14% of the company’s stock.

Cerus Company Profile

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products.

Insider Buying and Selling by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply